IP Library › Granted Patent US 7,939,090
Granted Patent B2
US 7,939,090 · App. 10/575,438 · Granted May 10, 2011

System and method for the treatment of cancer, including cancers of the central nervous system

Assignee: Cedars-Sinai Medical Center
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,939,090
App. No.
10/575,438
Granted
May 10, 2011
Kind
B2
Abstract

The invention relates to the treatment of cancer, and particularly to the treatment of cancers of the central nervous system, such as glioblastoma multiforme. A dual therapeutic approach is provided, including the administration of a dendritic cell-based cancer vaccine and a regimen of chemotherapy. The two therapies may be administered concurrently with one another and/or with an initial vaccination preceding chemotherapy. In various embodiments, the dendritic cell-based cancer vaccine includes either primed or unprimed dendritic cells; for instance, the dendritic cells may be autologous tumor antigen-presented dendritic cells. The dual therapeutic approach of the instant invention beneficially influences the chemosensitivity of a mammal with cancer.

Claims (14)

1. A method for treating a glioma in a mammal, the method comprising:

(a) administering at least one vaccination of dendritic cells (“DC”) to said mammal suffering from a glioma, wherein the at least one vaccination of DC comprises autologous DC that present autologous glioma antigens; and

(b) after glioma recurrence following (a), administering a regimen of chemotherapy to said mammal, wherein said regimen of chemotherapy includes the administration of at least one chemotherapeutic agent selected from the group consisting of temozolomide, procarbazine, vincristine, BCNU, CCNU, thalidomide, irinotecan, isotretinoin, imatinib, etoposide, and combinations thereof.

2. The method of claim 1 , wherein administering said at least one vaccination further comprises administering at least three vaccinations of DC.

3. The method of claim 1 , wherein each of said at least one vaccination of DC comprises from about 10 5 to about 10 7 DC.

4. The method of claim 1 , wherein each of said at least one vaccination of DC comprises about 10×10 6 to about 40×10 6 DC.

5. The method of claim 1 , wherein said glioma is glioblastoma multiforme.

6. The method of claim 1 , wherein said mammal is a human.

7. The method of claim 1 , wherein the DC are primed ex vivo with autologous glioma cells.

8. The method of claim 7 , wherein administering said at least one vaccination of DC comprises administering at least three vaccinations of DC.

9. The method of claim 7 , wherein each vaccination of DC comprises from about 10 5 to about 10 7 DC.

10. The method of claim 7 , wherein each vaccination of DC comprises about 10×10 6 to about 40×10 6 DC.

11. The method of claim 7 , wherein said glioma is glioblastoma multiforme.

12. The method of claim 7 , wherein said mammal is a human.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2006
From: WHEELER, CHRISTOPHER; DAS, ASHA; BLACK, KEITH L.
To: CEDARS-SINAI MEDICAL CENTER
Reel/Frame 017797/0031 →
Continuity (2)
Provisional Application 60513040 · Oct 21, 2003
Related Publication 20070020297A1 · Jan 25, 2007